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https://doi.org/10.1016/j.celrep.2021.108779SUMMARYIn the tumor microenvironment, senescent non-malignant cells, including cancer-associated fibroblasts
(CAFs), exhibit a secretory profile under stress conditions; this senescence-associated secretory pheno-
type (SASP) leads to cancer progression and chemoresistance. However, the role of senescent CAFs in
metastatic lesions and the molecular mechanism of inflammation-related SASP induction are not well un-
derstood. We show that pro-inflammatory cytokine-driven EZH2 downregulation maintains the SASP by
demethylating H3K27me3 marks in CAFs and enhances peritoneal tumor formation of gastric cancer
(GC) through JAK/STAT3 signaling in a mouse model. A JAK/STAT3 inhibitor blocks the increase in GC
cell viability induced by senescent CAFs and peritoneal tumor formation. Single-cell mass cytometry re-
vealed that fibroblasts exist in the ascites of GC patients with peritoneal dissemination, and the fibroblast
population shows p16 expression and SASP factors at high levels. These findings provide insights into the
inflammation-related SASP maintenance by histone modification and the role of senescent CAFs in GC
peritoneal dissemination.CONTEXT AND SIGNIFICANCE
Development of novel therapeutic strategy is required to over-
come the peritoneal dissemination in advanced GC patients.
However, conventional therapies do not demonstrate satis-
fying benefits in GC patients with peritoneal dissemination.
This obstacle may be caused by non-malignant cells, not can-
cer cells themselves. Our findings reveal the fundamental
mechanism by which inflammation-driven senescent CAFs
enhance peritoneal dissemination. We also identified the sig-
nificance of targeting senescent CAFs, as well as JAK/
STAT3 signaling in GC cells. This study demonstrates a prom-
ising therapeutic approach for GC peritoneal dissemination
driven by systemic inflammation.C
This is an open access article undINTRODUCTION
Gastric cancer (GC) is one of the most common cancers world-
wide and is the third leading cause of cancer-related deaths in
both men and women (Bray et al., 2018). Despite curative resec-
tion for advanced GCs, unresectable recurrence is often
observed, and the prognosis of recurrent GC patients remains
poor (Thomassen et al., 2014). The most frequent cause of GC
death is peritoneal metastasis, which is considered an indepen-
dent prognostic factor for poor prognosis (Chau et al., 2004).
Peritoneal metastasis is caused by cancer cell dissemination
into the peritoneal cavity from the primary organ. A poor under-
standing of the molecular mechanisms underlying the peritoneal
dissemination process hinders the development of an effectiveell Reports 34, 108779, February 23, 2021 ª 2021 The Author(s). 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
(legend on next page)






OPEN ACCESStreatment strategy for this condition. In advanced GCs, cancer
cells tend to interact with the tumor microenvironment, which
contains extracellular matrix, immune cells, and cancer-associ-
ated fibroblasts (CAFs), and the interaction enhances cancer
progression and metastasis through various cytokines and
growth factors (Kalluri, 2016; Quail and Joyce, 2013). Although
invasive cancer cells are likely to penetrate the gastric wall by in-
teracting with the tumor microenvironment and spread into the
peritoneal cavity, the role of non-malignant cells co-existing
with cancer cells in mediating peritoneal dissemination is still
unknown.
Chronic inflammation caused by Helicobacter pylori infection
is the main risk factor for the development of GC. Therefore,
various types of cells in the gastric mucosa are exposed to an
inflammatory environment for long periods that induces epige-
netic alterations (Ushijima and Hattori, 2012; Ishimoto et al.,
2015). Moreover, several lines of evidence indicate that senes-
cent cells in the tumor microenvironment survive and develop a
secretory profile composed mainly of inflammatory cytokines.
This phenomenon is called the senescence-associated secre-
tory phenotype (SASP) (Coppé et al., 2008; Gorgoulis et al.,
2019), which enhances the proliferation and invasion of the sur-
rounding cancer cells; in addition, this phenomenon promotes
angiogenesis by recruiting macrophages and enhances the
immunosuppressive microenvironment in a context-dependent
manner (Kelly et al., 2007; Ruhland et al., 2016; Lee and
Schmitt, 2019).
In contrast to the SASP as a chronic event, an acute stress-
associated phenotype (ASAP) before the appearance of senes-
cence markers is recognized as the rapid cellular response to
various stresses, such as treatment by cytotoxic agents (Gilbert
and Hemann, 2010). Although the transition from an ASAP to a
chronic SASP has remained an intriguing topic, little is known
about the mechanism. Chronic inflammation is deeply impli-
cated in cellular senescence (Jurk et al., 2014).Moreover, inflam-
masome-mediated IL-1 signaling controls the SASP (Acosta
et al., 2013), suggesting that cancer-related inflammation could
be involved in the transition from an ASAP to a SASP. The pre-
sent study was conducted to investigate the molecular mecha-
nism of the transition during cancer-related inflammation andFigure 1. CAFs stimulated with proinflammatory cytokines undergo
signaling
(A) Growth assay of 6 NFs and CAFs at the same passage number incubated fo
(B) WB analysis of p16 and p15 in 3 NFs and CAFs at the same passage numbe
(C) Telomere length of 6 pairs of NFs and CAFs. The dot plots show the telomer
(D) Growth assay of 3 NFs for 3 days after treatment with 3CKs (**p < 0.01; n.s.,
(E) Growth assay of 3 CAFs for 3 days after treatment with 3CKs (*p < 0.05 and
(F) WB analysis of p16, p15, and Lamin B1 in NFs, untreated or treated with 3CK
(G) WB analysis of p16, p15, and Lamin B1 in CAFs, untreated or treated with 3C
(H) SA-b-gal staining of the control (3CKs() day 0), cultivated for 7 days with con
after treatment with 3CKs (3CKs(+) day 7). Scale bars, 300 mm. The graph shows t
(*p < 0.05 and **p < 0.01; n = 3).
(I) Growth assay of 3 CAF lines treated with or without 3CKs for 10 days (**p < 0
(J) Immunofluorescence staining formarkers of gH2AX and phospho-Ser/Thr ATM
after the 3CK treatment; long-term passaged CAFs served as a positive control. T
for both gH2AX and pST/Q. At least 100 cells were counted in each group (**p <
(K) WB analysis of NF-kB (p65) in 3 CAF lines treated with or without 3CKs. a-Tu
histone 3 (H3) was similarly analyzed as a loading control for nuclear proteins.
(L) Immunofluorescence staining for NF-kB together with nuclear staining with Dto reveal the role of senescent non-malignant cells in the meta-
static process in GC patients.
RESULTS
CAFs influenced by pro-inflammatory cytokines tend to
shift to the senescent state through the activation of
nuclear factor kB (NF-kB) signaling
We isolated primary fibroblasts, CAFs, and normal fibroblasts
(NFs) from resected tissues from GC patients and cultured the
primary fibroblasts in vitro. These primary fibroblasts (NFs and
CAFs) were confirmed to express the primary fibroblast marker
CD90 by flow cytometry and to express four representative
genes (RHBDF2, IL7R, CADM1, and TM4SF1) that are highly ex-
pressed in CAFs according to the RNA sequencing data in our
previous study (Ishimoto et al., 2017) (Figures S1A and S1B).
Based on our observations, we found that CAFs grew slower
than NFs. Thus, we first examined the growth rate of NFs and
CAFs at the same number of passages after isolation and
showed that the growth rate of NFs was higher than that of
CAFs (Figure 1A). We next examined the expression of
p16INK4a (p16) and p15INK4b (p15), which are implicated in cell-
cycle regulation and cellular senescence, via western blot (WB)
analysis of NFs and CAFs at the same passage number. How-
ever, the expression of these proteins was hardly detected and
was almost the same for both NFs and CAFs (Figure 1B). We
also compared the telomere length using six NFs genomic
DNA samples from paired NFs and CAFs at the same passage
number. Although the length of the telomeres in NFs had a ten-
dency to be slightly longer than that in CAFs, the average telo-
mere length in NFs was not significantly different from that in
CAFs (Figure 1C). These modest differences may be explained
by epigenetic alterations in NFs during chronic inflammation
caused by H. pylori infection (Maeda et al., 2020).
As shown in our previous study, three inflammatory cytokines
(3CKs), interleukin-1a (IL-1a), (IL-1b), and tumor necrosis factor a
(TNF-a), endow NFs with a CAF-like morphology, and high
expression of 3CKs in GC tissues was significantly associated
with a poor prognosis for patients with GC, although the expres-
sion level of each individual cytokine was not associated with thea shift in the senescence status through the activation of NF-kB
r 4 days (**p < 0.01, n = 6).
r (3). b-Actin was similarly analyzed as a loading control.
e length.
not significant, n = 3).
**p < 0.01; n = 3).
s. b-Actin was similarly analyzed as a loading control.
Ks. b-Actin was similarly analyzed as a loading control.
ditioned medium without passaging (3CKs() day 7), and cultivated for 7 days
he percentage of SA-b-gal+ cells. At least 100 cells were counted in each group
.01, n = 3).
/ATR (pST/Q) substrate together with nuclear staining with DAPI in CAFs 5 days
he graph shows the percentage of nuclei that contain double-positive staining
0.01, n = 3).
bulin was similarly analyzed as a loading control for cytoplasmic proteins, and
API in CAFs treated with or without 3CKs. Scale bars, 50 mm.
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OPEN ACCESSprognosis of patients with GC (Ishimoto et al., 2017). Based on
these findings, we investigated the effects of 3CKs on CAFs
and NFs according to the protocol (Figure S1C). We examined
themorphological differences in the responses to 3CKs between
NFs and CAFs and found that both NFs and CAFs treated with
3CKs showed similar spindle-shaped cell bodies, unlike the con-
trol (Figure S1D). However, the growth rate of CAFs was much
more strongly suppressed by 3CK stimulation than was that of
NFs (Figures 1D and 1E). Subsequently, WB analysis showed
that 3CKs markedly increased the expression of p16 and p15
and decreased the expression of Lamin B1, as senescence
markers, in CAFs compared with NFs (Figures 1F and 1G). These
results implied that CAFs are likely to shift to a senescent state
under exposure to 3CKs. In addition, senescence-associated
b-galactosidase (SA-b-gal) staining was conducted to detect se-
nescent cells, and the population of SA-b-gal+ senescent cells
was markedly increased in CAFs treated with 3CKs (Figure 1H).
We performed the growth assay over a long period and assessed
the DNA damage response, which is known to be a character-
istic of senescent cells, to further examine whether 3CK stimula-
tion induces irreversible cellular senescence. Consequently,
growth arrest was induced in three independent CAF lines
treated with 3CKs, and gH2A histone family member X
(gH2AX) and phosphorylation of the consensus target se-
quences (pST/Q) accumulated in CAFs treated with 3CKs and
in senescent CAFs induced by long-term passaging (Figures 1I
and 1J) (Takahashi et al., 2017).
Several studies have demonstrated that NF-kB transcription
factors are involved in senescence (Salminen et al., 2012). In
general, the pro-inflammatory cytokines IL-1a, IL-1b, and TNF-
a, are known to be upstream of NF-kB signaling. Thus, we con-
ducted WB analyses and immunofluorescence staining to
examine the nuclear translocation of p65 and confirmed the
translocation in CAFs treated with 3CKs (Figures 1K and 1L).
Moreover, we conducted an NF-kB loss-of-function study using
NF-kB (p65) small interfering RNA (siRNA) to show the impor-
tance of NF-kB signaling in the senescent state in CAFs treated
with 3CKs. The intracellular reactive oxygen species (ROS) level
has been shown to cause DNA damage and induce cell-cycle ar-
rest in oncogene-induced senescence (Kuilman et al., 2008; Ta-
kahashi et al., 2018). We showed that NF-kB (p65) knockdown
significantly decreased the intracellular ROS level and the accu-
mulation of gH2AX and pST/Q in CAFs treated with 3CKs (Fig-
ures S2A–S2C). These findings strongly support the hypothesis
that activated NF-kB signaling leads to cellular senescence in
CAFs treated with 3CKs.
Depletion of H3K27me3marks by EZH2 downregulation
leads to the maintenance of SASP factors in S-CAFs
To further examine the changes in the molecular profile in CAFs
treated with 3CKs, we conducted comprehensive gene expres-
sion analysis by RNA sequencing. In addition, the gene set
enrichment analysis (GSEA) of RNA sequencing data revealed
that NF-kB target and senescence-related gene sets were en-
riched in CAFs treated with 3CKs compared with control CAFs
(Figures 2A and 2B). Because NF-kB signaling is a major inducer
of the SASP (Salminen et al., 2012), we next examined whether
senescent CAFs induced by the 3CK treatment, defined as S-4 Cell Reports 34, 108779, February 23, 2021CAFs, exhibit the SASP. RNA sequencing data revealed that
the expression of 21 genes previously reported as SASP factors
(Prime et al., 2017) was strongly induced in S-CAFs treated with
3CKs (Figure 2C). We next confirmed the induction of major
SASP factors by qRT-PCR (Figure 2D). NF-kB (p65) knockdown
also significantly decreased the expression of SASP factors (Fig-
ure S2D). We examined the expression of 6 SASP factors 7 days
after 3CK treatment to further assess whether this induction is an
acute response mediated by the activation of NF-kB signaling
and notably found that the induced expression of these factors
was maintained at high levels for 7 days (Figure S3A). The
expression of these SASP factors in S-CAFs treated with 3CKs
was substantially higher than in untreated CAFs after long-term
passaging (Figures S3B and S3C).
Some Polycomb group (PcG) proteins are downregulated,
leading to the loss of trimethylation of lysine 27 on histone H3
(H3K27me3) at the CDKN2A locus, which results in the upregu-
lation of p16 during senescence (Bracken et al., 2007). One of the
PcG components, EZH2, is the histone lysine methyltransferase
that catalyzes the H3K27me3. The inhibition of EZH2 activity in-
duces senescence in the absence of DNA damage by depleting
H3K27me3 marks and activating the p16 and SASP genes (Ito
et al., 2018). This led us to hypothesize that the loss of the
H3K27me3 marks by EZH2 downregulation may lead to the
maintenance of SASP factors in S-CAFs by 3CK treatment. To
address this hypothesis, we examined the time course of the
p16, EZH2, and H3K27me3 marks. The WB analysis showed
decreased expression of EZH2 and increased levels of p16 five
days after the 3CK treatment; in addition, H3K27me3 marks
were depleted within 7 days after 3CK treatment (Figure 2E).
EZH2-overexpressing CAFs were generated and the
H3K27me3 status was examined after treatment with 3CKs to
further examine the importance of EZH2 downregulation in the
maintenance of SASP factors in S-CAFs treated with 3CKs.
The level of H3K27me3 marks was maintained, and the expres-
sion of p16 was not increased in EZH2-overexpressing CAFs
7 days after the 3CK treatment (Figure 2F). Notably, the expres-
sion levels of SASP factors were significantly decreased in
EZH2-overexpressing CAFs compared with mock transfected
CAFs 7 days after the 3CK treatment (Figure 2G). Moreover,
the chromatin immunoprecipitation (ChIP) sequencing analysis
revealed a marked decrease in the H3K27me3 modification at
the promoter region of SASP factors in CAFs treated with
3CKs, whereas the modifications were not changed in EZH2-
overexpressing CAFs treated with 3CKs (Figures 2H and 2I).
Based on these results, the demethylation of H3K27me3 marks
induced by EZH2 downregulation plays a crucial role in themain-
tenance of SASP factors in S-CAFs.
S-CAFs enhance GC cell growth through Janus kinase/
signal transducer and activator of transcription 3 (JAK/
STAT3) signaling
SASP factors are commonly considered to enhance cancer
progression (Coppé et al., 2008; Yoshimoto et al., 2013).
Thus, we examined the growth of the GC cell lines OCUM-
2MD3 and NUGC3 treated with the conditioned medium
(CM) of CAFs (CAF-CM) or S-CAFs (S-CAF-CM). Compared
with the growth of GC cells treated with normal medium
Figure 2. Depletion of H3K27me3 marks by EZH2 downregulation leads to maintenance of the SASP in CAFs
(A) Workflow of the genomic analysis conducted to examine the senescent state of CAFs treated with 3CKs.
(B) GSEA graphs for the upregulated signatures of NF-kB-related genes and senescence-related genes in 3 CAF lines 3 days after the 3CK treatment.
(C) Heatmap showing differentially expressed genes in 3 CAF lines 3 days after the 3CK treatment. A total of 21 uniquely expressed SASP-related genes for CAFs
treated with 3CKs are indicated in the boxes.
(D) SASP factors that were upregulated by 3CKs, as validated by qRT-PCR (**p < 0.01; n.s., not significant, n = 3).
(E) WB analysis of p16, EZH2, and H3K27me3 levels in CAFs at the indicated time points after 3CK treatment. Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) andH3were similarly analyzed as loading controls. Graph shows the normalization of the H3K27me3 level to the total H3 level inWB analysis (**p < 0.01,
n = 3).
(F and G) CAFs were transfected with an empty vector (mock) or EZH2 overexpression vector and then treated with or without 3CKs. Each of the 4 groups was
evaluated 7 days after the 3CK or control treatment.WB analysis of p16, EZH2, and H3K27me3 levels in each of the 4 groups. GAPDH andH3 levels were similarly
analyzed as loading controls (F). SASP factors analyzed using qRT-PCR in each 3CK treatment group (*p < 0.05 and **p < 0.01; n = 3) (G).
(H) Representative for duplicate ChIP sequencing (seq) data for SASP gene loci in each group.
(I) Heatmap quantifying the highlighted area, where the signal intensities are located ±2 kb from the transcription start site in the promoter regions of SASP genes
in duplicate data.
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OPEN ACCESS(NM) and CAF-CM, the growth of GC cells treated with S-
CAF-CM was significantly increased (Figure 3A). We exam-
ined the status of various kinases using WB analysis to verify
which signaling pathway was involved in the enhanced growth
of GC cells treated with S-CAFs and observed a substantial
increase in the phosphorylation of STAT3 in cells treated
with S-CAF-CM (Figure 3B). Moreover, we investigated the
importance of p-STAT3 activation in GC cell growth enhanced
by S-CAFs using STAT3 knockdown by specific siRNA and
WP1066, a potent inhibitor of the JAK/STAT3 pathway (Kong
et al., 2008). We examined the viability of OCUM-2MD3 and
NUGC3 cells treated with various concentrations of WP1066
and found that 5 mM WP1066 effectively blocked JAK/
STAT3 activation by S-CAF without cytotoxicity (Figures 3C
and S4A). Notably, WP1066 more effectively suppressed the
viability of GC cells treated with S-CAF-CM than GC cells
without S-CAF-CM (Figure S4B) and remarkably decreased
the number of GC cells treated with S-CAF-CM compared
with GC cells without S-CAF-CM (Figure 3D). Similarly,
STAT3 knockdown significantly decreased the number of
GC cells treated with S-CAF-CM (Figures S4C–S4F). These
findings imply that the growth of GC cells treated with S-
CAF-CM depends on JAK/STAT3 signaling and that blockade
by WP1066 leads to reductions in GC cell viability and growth.
In addition, the growth of GC cells treated with recombinant
IL-6 was significantly increased, and WP1066 effectively
blocked JAK/STAT3 pathway activation and reduced the
number of GC cells in the group treated with recombinant
IL-6 (Figures 3E and 3F). These findings suggest that among
the SASP factors, IL-6 has a prominent effect on GC cell
growth.
GC patients with peritoneal dissemination show
systemic inflammation, and ascites from these patients
contains p16+ fibroblasts that highly express SASP
factors
We compared serum levels of C-reactive protein (CRP), an in-
flammatory marker, the proportion of neutrophils, and the
number of white blood cells in patients with early and
advanced GC presenting without or with peritoneal dissemi-
nation to determine the stage at which CAFs were affected
by inflammatory cytokines during the process of GC progres-
sion. Intriguingly, significantly higher serum CRP levels and
proportions of neutrophils were detected in patients with GC
presenting with peritoneal dissemination than in the other
groups (Figure 4A). This result suggests that systemic inflam-
mation occurs in GC patients with peritoneal dissemination.Figure 3. JAK/STAT3 signaling activation by S-CAFs enhances GC cel
(A) Growth assay of OCUM-2MD3 and NUGC3 cells, untreated and treated wi
induced by 3CKs (*p < 0.05 and **p < 0.01; n = 3).
(B)WB analysis of p-STAT3, p-ERK1/2, p-p38, and p-AKT levels in OCUM-2MD3 a
for 10 min.
(C) WB analysis of p-STAT3, p-ERK1/2, p-p38, and p-AKT levels in OCUM-2MD
120 min.
(D) Growth assays of OCUM-2MD3 and NUGC3 cells treated with S-CAF-CM, v
(E) WB analysis of p-STAT3, p-ERK1/2, p-p38, and p-AKT levels in OCUM-2MD
(F) Growth assays of OCUM-2MD3 and NUGC3 cells treated with IL-6, vehicle (DGiven this finding, we presumed that the fibroblasts in the as-
cites of GC patients with peritoneal dissemination contain a
senescent population exhibiting the SASP. We isolated
CD90+/platelet-derived growth factor receptor a+ (PDGFRa+)
mesenchymal cells, including fibroblasts, epithelial cell adhe-
sion molecule-positive (EpCAM+) cancer cells, and CD45+ he-
matopoietic cells, from the ascites of patients with GC (Fig-
ures 4B and S5A) and examined the expression of SASP
factors to investigate this possibility. Notably, all SASP factors
were expressed at higher levels in CD90+/PDGFRa+ fibro-
blasts than in the other populations (Figure 4C). Moreover,
we performed single-cell mass cytometry (CyTOF) using asci-
tes from 5 patients with GC presenting peritoneal dissemina-
tion and the ascites of 2 patients with liver cirrhosis (LC) as a
control, and found that p16-high fibroblasts were more
frequently detected in the ascites from patients with GC
than in the ascites from patients with LC (Figure 4D). Further
analysis of the ascites from patients with GC revealed signif-
icantly higher expression of p16 and IL-6 in fibroblasts than
in the other cell populations (Figure 4E). In addition, we
compared the IL-6 expression level between p16-high and
p16-low fibroblasts and detected significantly higher expres-
sion in p16-high fibroblasts than in p16-low fibroblasts derived
from the ascites from patients with GC (Figures 4F and S5B).
These findings suggest that p16+ fibroblasts exist in the asci-
tes of GC patients with peritoneal dissemination and exhibit
the SASP.
S-CAFs enhance peritoneal tumor formation through
JAK/STAT3 signaling in vivo
Basedon the above findings,weconductedperitoneal dissemina-
tion model experiments using OCUM-2MD3 cells to evaluate the
role of S-CAFs in the development of peritoneal dissemination
in vivo. The peritoneal tumors of OCUM-2MD3-inoculated mice
treated with S-CAF-CM for 30 days were significantly larger than
tumors from the other two groups, and weight loss was not
observed (Figures 5A and S6A). In addition, the serum CRP levels
indicating systemic inflammationwere also significantly increased
in OCUM-2MD3-inoculated mice treated with S-CAF-CM (Fig-
ure 5B).We further assessed the p-STAT3 levels in tumors in these
3groupsbyWBanalysis and immunohistochemical (IHC) staining.
The tumor cells from the OCUM-2MD3-inoculated mice treated
with S-CAF-CM showed higher p-STAT3 levels than the mice in
the other 2 groups (Figures 5C–5E). Supporting the findings
from previous reports indicating that STAT-3 activation induces
the expression of antiapoptotic proteins (Bhattacharya et al.,
2005), Bcl-2 expression was increased in the tumors of thel growth
th CAF-CM or S-CAF-CM for 3 days. We collected S-CAF-CM from S-CAFs
nd NUGC3 cells. Cells were untreated and treated with CAF-CM or S-CAF-CM
3 and NUGC3 cells treated with S-CAF-CM, vehicle (DMSO), or WP1066 for
ehicle (DMSO), or WP1066 for 3 days (*p < 0.05 and **p < 0.01; n = 3).
3 and NUGC3 cells treated with IL-6, vehicle (DMSO), or WP1066 for 120 min.
MSO), or WP1066 for 3 days (*p < 0.05 and **p < 0.01; n = 3).
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Figure 4. Malignant ascites of GC patients contains p16+ fibroblasts that highly express SASP factors
(A) Serum levels of CRP, white blood cells (WBCs), and the proportion of neutrophils in early GC patients and advanced GC patients with or without peritoneal
dissemination (*p < 0.05 and **p < 0.01; n.s., not significant, early GC patients, n = 30; advanced GC patients without peritoneal dissemination, n = 30; and
advanced GC patients with peritoneal dissemination, n = 15).
(B) Workflow of sorting 100 cells of each labeled population (CD90/platelet-derived growth factor receptor a [PDGFR-a], EpCAM, and CD45) and collection of
their mRNA from GC patients with ascites.
(C) SASP factors of each population validated by qRT-PCR (**p < 0.01; n = 3).
(D) Histograms represent the arcsinh-transformed p16 expression normalized to a 0–5 range between the GC malignant ascites and cirrhosis ascites groups.
(E) t-SNE plots with labeled populations (CD90/PDGFR-a, EpCAM, and CD45) and heatmap showing the intensity of p16 and IL-6. Colors show row-normalized Z
score of gene expression values. The graph shows the quantification of the expression levels of p16 and IL-6 (**p < 0.01; n = 5).
(F) Histograms represent the expression of IL-6 between the p16-high and p16-low groups. The graph shows the quantification of the expression level of IL-6 in
each group (*p < 0.05; n = 5).




Figure 5. JAK/STAT3 signaling activation by S-CAF enhances peritoneal tumor formation
(A) Representative images of OCUM-2MD3-bearing mice after daily intraperitoneal injections of CAF-CM, S-CAF-CM, or normal medium. The graph shows the
quantification of the tumor masses of each group (day 30) (**p < 0.01; n = 8).
(B) ELISA of CRP in the serum of each group of OCUM-2MD3-bearing mice (**p < 0.01; n = 3).
(C) WB analysis of p-STAT3 and Bcl-2 in the implanted OCUM-2MD3 cells of each group. The graph shows the normalization of p-STAT3 to total STAT3 and the
normalization of Bcl-2 to total b-actin (*p < 0.05 and **p < 0.01; n = 3).
(legend continued on next page)






OPEN ACCESSOCUM-2MD3-inoculated mice treated with S-CAF-CM (Fig-
ure 5C).Moreover, Ki67 and terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) staining showed significantly
higher viability of the tumor cells in the S-CAF-CM group than in
the other 2 groups (Figures 5F and 5G). In addition, the peritoneal
tumors of OCUM-2MD3-inoculated mice treated with recombi-
nant IL-6 for 30dayswere largeranddisplayedapoptosis inhibition
andsignificantlyhigherp-STAT3andBcl-2 levels than tumors from
mice in the control group (Figures S6B–S6E). Togetherwith the re-
sults of the in vitroexperiments, thesefindings suggest that among
the SASP factors, IL-6 enhances peritoneal tumor formation
through JAK/STAT3 signaling.
Because the expression levels of SASP factors were signifi-
cantly decreased in EZH2-overexpressing CAFs treated with
3CKs (Figure 2G), we next examined the effect of S-CAFs medi-
ated by EZH2 downregulation on peritoneal tumor formation.
The volumes of peritoneal tumors in the EZH2O/E-CAF-CMgroup
were significantly smaller than the S-CAF-CM group, and weight
loss was not observed (Figures 5H, 5I, and S6F). Moreover,
p-STAT3 and Bcl-2 levels in the tumor lysates of the EZH2 O/E-
CAF-CM group were markedly decreased compared with the
S-CAF-CM group (Figure 5J). These results indicate that S-CAFs
mediated by EZH2 downregulation activate JAK/STAT3 signaling
and promote peritoneal tumor formation by inhibiting apoptosis.
A JAK/STAT3 inhibitor effectively blocks the increase in
peritoneal tumor formation induced by S-CAFs in vivo
Finally, the OCUM-2MD3-inoculated mice treated with S-CAF-
CM were additionally administered WP1066 according to the
protocol (Figure 6A) to determine the therapeutic effect of the
JAK/STAT3 inhibitor in vivo. Although the WP1066 treatment
did not affect peritoneal tumor formation in mice that were not
treated with S-CAF-CM (Figures S7A–S7C), the volumes of peri-
toneal tumors in the S-CAF-CM+WP1066 treatment group were
significantly smaller than in the S-CAF-CM group, without weight
loss (Figures 6B, S7D, and S7E).We next compared the p-STAT3
levels in the tumorsbetween the2groupsbyWBanalysis and IHC
staining. Tumor cells in mice administered WP1066 showed
lower p-STAT3 andBcl-2 levels than those in S-CAF-CM-treated
mice (Figures 6C–6E). Moreover, Ki67 and TUNEL staining re-
vealed significantly lower viability of tumor cells in the mice
treated with WP1066 than tumor cells in the S-CAF-CM-treated
mice (Figures 6F and 6G). These results suggest that JAK/
STAT3 signaling plays critical roles in the S-CAF-enhanced anti-
apoptosis function and in peritoneal tumor formation in vivo.
DISCUSSION
Nonmalignant cells in the tumor microenvironment secrete
various growth factors, cytokines, and microvesicles, which(D–G) H&E staining (D) and IHC staining for p-STAT3 (E) and Ki67 (F) and immunofl
group. Scale bars, 100 mm. Each graph shows the quantification of the positive rat
(H) Schematic illustrating the experimental procedure (S-CAF, n = 6; EZH2 O/E-C
(I) Representative images of OCUM-2MD3-bearingmice treated daily with injectio
(EZH2 O/E)-CAFs-CM. The graph shows the quantification of the tumor masses
(J) WB analysis of p-STAT3 and Bcl-2 levels in implanted OCUM-2MD3 cells in eac
normalization of Bcl-2 to total b-actin (**p < 0.01; n = 3).
10 Cell Reports 34, 108779, February 23, 2021leads to the exacerbation of cancer in multiple processes
(Bu et al., 2019). Previous evidence has indicated that senes-
cent non-malignant cells exhibiting the SASP are induced by
various stresses, such as ROS, and promote cancer develop-
ment. Moreover, the anticancer drug-induced genotoxicity of
nonmalignant cells may alter the tumor microenvironment,
causing cellular senescence and drug resistance (Sun et al.,
2012; Demaria et al., 2017). TAK1 increases the expression
of zinc finger and SCAN domain containing 4 (Zscan4), a
zinc finger transcription factor, and activates p38 and phos-
phatidylinositol 3-kinase/AKT/mammalian target of rapamycin
(PI3K/AKT/mTOR) signaling to support persistent SASP
signaling induced by cytotoxic agents (Zhang et al., 2018). In-
vestigations using endothelial cells (ECs) have demonstrated
that ECs damaged by anticancer drugs exhibit an ASAP as
a rapid response to stress and are mechanistically distinct
from the SASP (Gilbert and Hemann, 2010, 2011). Genotoxic
damage signals are transmitted through master regulators
such as NF-kB, and this results in a diverse secretory program
that generates a proangiogenic, proinflammatory microenvi-
ronment (Sun and Nelson, 2012). We have now demonstrated
the mechanism of transition from an acute inflammatory
response to a SASP through NF-kB signaling activated by in-
flammatory cytokines in CAFs. Specifically, inflammatory cy-
tokines induced the acute inflammatory response through
the transient activation of NF-kB signaling and subsequent
depletion of the H3K27me3 marks by EZH2 downregulation
and led to the maintenance of SASP factors in S-CAFs. The
current finding delineates one of the molecular mechanisms
underlying the loss of H3K27me3, which is a distinct change
in CAFs, and epigenetic change is involved in the tumor-pro-
moting capacities of CAFs through the secretion of multiple
stem cell niche factors (Maeda et al., 2020).
Senescent hepatic stellate cells promote obesity-associated
hepatocellular carcinoma (HCC) development in mice by
increasing the levels of deoxycholic acid produced by gut bacte-
ria (Yoshimoto et al., 2013). Senescent CAFs secrete excessive
amounts of IL-8 and promote pancreatic ductal adenocarcinoma
(PDAC) invasion and metastasis, whereas an inhibitor of the IL-8
receptor blocked themotility of PDAC cells (Wang et al., 2017). In
addition, IL-6 production in the tumor microenvironment leads to
the activation of JAK/STAT3 signaling in both tumor cells and
tumor-infiltrating immune cells, which can promote cancer pro-
gression (Johnson et al., 2018), and IL-6, among the SASP fac-
tors derived from senescent cells, causes chemoresistance in
several kinds of tumors (Bent et al., 2016; Canino et al., 2012).
Our current findings demonstrated that S-CAFs exhibiting the
SASP promote peritoneal tumor formation through JAK/STAT3
signaling in amousemodel. Moreover, we showed the existence
of fibroblasts harboring the characteristics of the SASP in theuorescence for TUNEL analysis (G) in the implanted OCUM-2MD3 cells of each
e. At least 100 cells were counted in each group (*p < 0.05 and **p < 0.01; n = 3).
AF, n = 6).
ns of S-CAF-CM (CAFs transfected with empty vector) or EZH2-overexpressing
in each group (*p < 0.05; n = 6).
h group. The graph shows the normalization of p-STAT3 to total STAT3 and the
Figure 6. The JAK/STAT3 inhibitor effectively blocks the peritoneal tumor formation enhanced by S-CAFs
(A) Timeline of the experimental procedure (S-CAF, n = 6; S-CAF + WP, n = 8).
(B) In vivo imaging system (IVIS) images of OCUM-2MD3-bearing mice treated with daily S-CAF-CM injections and treated with vehicle (DMSO, control) or 20mg/
kgWP1066 a total of 8 times for 3 weeks. Representative images of eachmouse group. The graph shows the quantification of the tumor sizes by in vivo luciferase
assays (**p < 0.01; S-CAF, n = 6; S-CAF + WP, n = 8).
(legend continued on next page)






OPEN ACCESSascites of GC patients with peritoneal dissemination. Previous
studies and the findings in the present article indicate that non-
malignant cells exhibiting the SASP may enhance peritoneal
dissemination and cancer progression in primary tumors.
Inflammation is a well-known hallmark of cancer that strongly
contributes to the development and progression of malignancies
(Hanahan and Weinberg, 2011). Systemic inflammation, similar
to the local immune response, involves cytokines and small in-
flammatory proteins and immune cells; however, these media-
tors are detectable in the systemic circulation and give rise
to the paraneoplastic symptoms observed in patients with
cancer. Moreover, circulating cytokines, chemokines, and ma-
trix-degrading proteins show similar functions in the systemic
circulation and local tumor microenvironment and are crucial
to the dissemination of tumors to distant sites (Diakos et al.,
2014). In fact, we demonstrated that serum CRP levels and the
proportion of neutrophils were significantly higher in GC patients
with than in those without peritoneal dissemination. This finding
implies that the local immune response in the peritoneal cavity
associated with peritoneal dissemination causes systemic
inflammation. Moreover, CRP is a member of the pentraxin fam-
ily and is released by hepatocytes in response to proinflamma-
tory cytokines, particularly IL-6 (Guthrie et al., 2013). Together
with these previous studies, our present findings suggest that
systemic inflammation in GC patients with peritoneal dissemina-
tion is enhanced by IL-6 derived from non-malignant cells in
ascites.
In summary, the proinflammatory cytokines IL-1a, IL-1b, and
TNF-a induce the activation of NF-kB signaling and cellular
senescence by promoting ROS accumulation in CAFs. Subse-
quently, the expression of SASP factors, particularly IL-6, is
maintained at a high level through the demethylation of
H3K27me3 marks by EZH2 downregulation, resulting in
enhanced peritoneal tumor formation through JAK/STAT3
signaling (Figure 6H). Given these findings, the disablement of fi-
broblasts harboring SASP in the ascites of GC patients with peri-
toneal dissemination may lead to the suppression of systemic
inflammation and inhibition of subsequent peritoneal tumor
formation.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
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Coppé, J.P., Patil, C.K., Rodier, F., Sun, Y., Muñoz, D.P., Goldstein, J., Nelson,
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DNase I, Amplification Grade Thermo Fisher Scientific Cat# 18068015
ERCC RNA Spike-In Mix Thermo Fisher Scientific Cat# 4456740
Halt Protease and Phosphatase Inhibitor
Cocktail (100X)
Thermo Fisher Scientific Cat# 78442
Human TruStain FcX BioLegend Cat# 422301
Incucyte NucLight Rapid Red Reagent for
nuclear labeling
Essen BioScience Cat# 4717
InSolution STAT3 Inhibitor III, WP1066 Millipore Cat# 573129
Klenow Fragment (30-50 exo-) New England Biolabs Cat# M0212
Lipofectamine RNAiMAX Transfection
Reagent
Thermo Fisher Scientific Cat# 13778-150
LipofectamineTM 3000 Thermo Fisher Scientific Cat# L3000015
Maxpar Fix I Buffer Fluidigm Cat# 201065
Maxpar Perm-S Buffer Fluidigm Cat# 201066
Maxpar Water Fluidigm Cat# 201069
MluI-HF New England Biolabs Cat# R3198S
NEBuffer 2 New England Biolabs Cat# B7002
NP40 Cell Lysis Buffer Thermo Fisher Scientific Cat# FNN0021
Oligo(dT)12-18 Primer Thermo Fisher Scientific Cat# 18418012
Oligo(dT)18 Primer Thermo Fisher Scientific Cat# SO131
Random Primers Thermo Fisher Scientific Cat# 48190011
RealTime ready Cell Lysis Buffer Roche Cat# 7248431001
RIPA buffer Thermo Fisher Scientific Cat# 89901
RNaseOUT Recombinant Ribonuclease
Inhibitor
Thermo Fisher Scientific Cat# 10777019
RNasin Plus RNase Inhibitor Promega Cat# PAN2615
RPMI-1640 FUJIFILM Wako Pure Chemical
Corporation
Cat# 189-02145
SuperScript III Reverse Transcriptase Thermo Fisher Scientific Cat# 18080093
T4 Gene 32 Protein New England Biolabs Cat# M0300
VivoGlo Luciferin, In Vivo Grade Promega Cat# P1043
Critical commercial assays
Absolute Human Telomere Length
Quantification qPCR Assay Kit
ScienCell Cat# 8918
DCFDA/H2DCFDA-Cellular ROS Assay Kit Abcam Cat# ab113851
Lentiviral High Titer Packaging Mix TaKaRa Cat# 6194
miRneasy Mini Kit QIAGEN Cat# 74106
Mouse C-Reactive Protein/CRP Quantikine
ELISA Kit
R&D Systems Cat# MCRP00
PrimeScript RT reagent Kit TaKaRa Cat# RR037A
(Continued on next page)





REAGENT or RESOURCE SOURCE IDENTIFIER
QIAamp DNA Mini Kit QIAGEN Cat# 51306
QIAquick PCR Purification Kit (250) QIAGEN Cat# 28106
Senescence Detection Kit BioVision Cat# K320
ThruPLEX DNA-seq Kit TaKaRa Cat# R400674
TUNEL Assay Kit - BrdU-Red Abcam Cat# ab66110
Zombie Green Fixable Viability Kit BioLegend Cat# 423111
Deposited data
RNA sequencing data This paper DRA008307
ChIP sequencing data This paper DRA011193
Experimental models: cell lines
Human: OCUM2MD3 N/A RRID:CVCL_8385
Human: NUGC3 Japanese Collection of Research
Bioresources Cell Bank
Cat# JCRB0822; RRID:CVCL_1612
Lenti-X 293T cell line TaKaRa Cat# Z2180N
Experimental models: organisms/strains
Mouse: BALB/cAJcl-nu/nu CLEA Japan, Inc N/A
Oligonucleotides
Primer sequences see Table S2. N/A
Recombinant DNA
Silencer Select Negative Control No. 1
siRNA
Thermo Fisher Scientific Cat# 4390843
siRNA targeting RELA Thermo Fisher Scientific Assay ID: s11914 Cat# 4427038
siRNA targeting STAT3 Thermo Fisher Scientific Assay ID: s744 Cat#4427038
Recombinant Human IL-6 PeproTech Cat# 200-06
Recombinant Human IL-1a Bay Bioscience Cat# 8019
Recombinant Human IL-1b Bay Bioscience Cat# 8018
Recombinant Human TNF-a Bay Bioscience Cat# 8329
Software and algorithms
2100 Bioanalyzer Agilent https://www.chem-agilent.com/contents.
php?id=51
Bowtie2 Langmead and Salzberg, 2012 http://bowtie-bio.sourceforge.net/bowtie2/
index.shtml
BZ-X Analyzer Keyence https://www.keyence.co.jp/
FastQC Babraham Bioinformatics http://www.bioinformatics.babraham.ac.
uk/projects/fastqc/
FlowJo 3.3 software BD Biosciences https://www.bdbiosciences.com/jp/
instruments/software/flowjo/index.jsp
FlowSOM (Van Gassen et al., 2015) http://bioconductor.org/packages/release/
bioc/html/FlowSOM.html
ImageJ NIH https://imagej.nih.gov/ij/
Incucyte S3 Live-Cell Analysis System Essen BioScience https://www.essenbioscience.com/ja/
products/incucyte/incucyte-s3/
JMP version 9 SAS Institute https://www.sas.com/ja_jp/home.html
LUNA-II Automated Cell Counter Logos Biosystems Cat# T13001
NextSeq 500 Illumina https://www.biocompare.com/
23967-Next-Generation-Sequencers/
11182085-NextSeq-500-System/








Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Takat-
sugu Ishimoto (taka1516@kumamoto-u.ac.jp).
Materials availability
All materials will be made available upon reasonable request.
Data and code availability
All data are available within the article. Sequencing data that support the funding of this study have been deposited in DDBJ under the
accession numbers listed below. RNA sequencing: DRA008307. ChIP sequencing: DRA011193.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Patients and tissue samples
Laboratory data were obtained from patients (ages 56-78 years of either sex) who underwent a gastrectomy at the Department of
Gastroenterological Surgery, Kumamoto University Hospital (Kumamoto, Japan). Primary CAFs and NFs were isolated from patients
(ages 52-74 years of either sex) with GC who underwent gastrectomy without preoperative treatment at Kumamoto University, Sai-
seikai Kumamoto Hospital after informed consent was obtained from each patient. Serum samples were obtained from patients at
the Department of Gastroenterological Surgery, Kumamoto University Hospital (Kumamoto, Japan). The study was approved by the
Medical Ethics Committee of Kumamoto University (Approval Number: 1277) and Saiseikai Kumamoto Hospital (Approval Number:
362).
Cell lines and cell culture
The human GC cell line NUGC3 was obtained from the Japanese Collection of Research Bioresources Cell Bank and the RIKEN Bio-
Resource Center Cell Bank. OCUM-2MD3 cells were derived from a peritoneal metastatic nodule after orthotopic implantation of
OCUM-2M cells, which were derived from a 49-year-old female with scirrhous gastric cancer in 1992. Human gastric fibroblast
cell lines were derived from the surgically excised gastric tissue of 100 patients with GC. CAFs were established from the surgically
excised gastric wall tumor, and NFs were from the non-tumor gastric wall tissue. These cells were cultured in RPMI 1640 containing
10% FBS (normal medium) and incubated at 37C with 5% CO2.
Animals
Eight- to ten-week-old male BALB/c nude mice (Clea Japan, Shizuoka, Japan) were housed in a room under stable temperature and
humidity on a 12 hour-light and dark cycle. Both water and food were supplied adlibitum. All animal procedures and studies were




For conditioned media experiments, CAFs were treated for 24 hours with three inflammatory cytokines (3CKs), IL1a, IL1b, and TNFa,
at 10 ng/ml each (Bay Bioscience, Japan) in RPMI 1640 containing 10% FBS. Media were collected, centrifuged to remove debris,
and filtered with a Millex Sterile Filter Unit, 0.22 mm (Millipore). CAF-conditioned medium (CM) was collected from CAFs, and S-CAF-
CM was collected from S-CAFs induced by 3CKs for 24 hours and then cultured in normal medium.
Drugs and recombinant proteins used for in vitro experiments
Recombinant human IL-6 (PeproTech) and the JAK/STAT3 inhibitor WP1066 (Millipore) were purchased. Cells were treated with
10 ng/ml recombinant human IL-6 or 5 mM WP1066 for each in vitro experiment.
Animal experiments
Eight- to ten-week-old male BALB/c nudemice (Clea Japan, Shizuoka, Japan) were housed in Kumamoto University (Approval Num-
ber: F29-189). OCUM-2MD3 cells (5.03 106) were implanted through intraperitoneal injection. Tumor weight and body weight were
evaluated in these mice. Three groups of mice were assessed for tumor development: 1) tumor-bearing mice treated with normal
medium (NM) (n = 8), 2) tumor-bearing mice treated with CAF-CM, and 3) tumor-bearing mice treated with S-CAF-CM. The mice
were treated with each CM (200 ml/day) via an intraperitoneal injection every day for 30 days. The mice were sacrificed 30 days after
tumor cell inoculation. For the JAK/STAT3 inhibitor (WP1066) study, two groups of tumor-bearing mice were anaesthetized by
isoflurane inhalation, and tumor growth was assessed using an in vivo imaging system (Caliper IVIS Kinetic In Vivo Optical Imaginge4 Cell Reports 34, 108779, February 23, 2021
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OPEN ACCESSSystem) after a luciferin injection (200 mg/kg). Two groups of mice treated with daily S-CAF-CM were assessed for tumor develop-
ment and were either treated with vehicle (DMSO, control) or 20 mg/kg WP1066 a total of 8 times for 3 weeks. Control mice received
volumes of DMSO equivalent to the volumes of WP1066 used to treat the mice. For the recombinant IL-6 study, tumor-bearing mice
were injected with 200 ng/mouse of recombinant human IL-6 or 200 mL of PBS a total of 12 times for 30 days.
DNA and RNA extraction
Genomic DNA and total RNA were extracted from cultured cells using a QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany) and a
miRNeasy Mini Kit (QIAGEN), respectively, according to the manufacturer’s instructions.
Quantitative reverse transcription-PCR
Complementary DNA (cDNA) was reverse transcribed from total RNA using SuperScript III, RNaseOUT, Recombinant Ribonuclease
Inhibitor, Random Primers and Oligo(dT)12–18 Primer (Thermo Fisher Scientific). Quantitative reverse transcriptase (qRT)-PCR was
performed using the TaqMan Probe method. All primers and probe sets were designed by the Universal Probe Library Assay Design
Center. All primers were synthesized by GeneNet, and all probes were purchased from Roche Diagnostics. The qRT-PCR assay was
performed as previously described (Ishimoto et al., 2017). Primer and probe sequences for each Custom TaqMan Gene Expression
Assay are listed in Table S2.
RNA sequencing
RNA sequencing was performed by Liaison Laboratory Research Promotion Center (LILA) (Kumamoto University) using the method
described below. A 2100 Bioanalyzer (Agilent) was used to detect the concentration and purity of the total RNA. All samples with an
RNA integrity number (RIN) > 8.0 were used for sequencing. A NextSeq 500 (Illumina) instrument was used for the analysis, and the
data were converted to Fastq files. The quality control of the data was performed with FastQC. Then, the filtered reads were mapped
to the UCSC hg19 reference genome using HISAT2 (v2.1.0). The fragments per kilobase of exon per million mapped reads (FPKM)
values were calculated using Cufflinks (v2.2.1) software. Significant genes were extracted using Cuffdiff (p < 0.05).
Chromatin IP sequencing
ChIP-seq was performed as described previously (Kubota et al., 2019). CAFs were fixed with 0.5% paraformaldehyde at 37C for
5 min and then lysed. Cells were sonicated 15 times at a 50% amplitude for 10 s each. Samples were incubated with anti-
H3K27me3 antibody-conjugated (Abcam) or anti-mouse IgG-conjugated Dynabeads at 4C overnight. Input and immunoprecipi-
tates were incubated at 65C for 4 h to reverse cross-links, and DNA was purified using the QIAquick PCR Purification Kit (250)
(QIAGEN, #28106). ChIP-seq libraries were generated using the ThruPLEX DNA-seq kit (Takara). Bowtie2 (version 2.2.6; default pa-
rameters) was used to map the reads to the reference genome (UCSC/hg19) (Langmead and Salzberg, 2012). Bedtools and HOMER
(version 4.9) were used to count reads and assess reads coverage. ChIP-sequencing data were deposited in the DDBJ database
under the accession number DRA011193.
Expression vectors
The human EZH2 cDNAwas amplified with a forward primer (50- GAATAATCATGGGCCAGACTGGGAAGAAATCTG-30) and a reverse
primer (50- ATGTCAAGGGATTTCCATTTCTCTTTCGATGC-30) using cDNA isolated from CMK cells as a template, and the product
was ligated into pCR-Blunt II-TOPO (Invitrogen). The full sequence of the EZH2 cDNA was validated by Sanger sequencing. The
ORF of EZH2 was PCR amplified with a forward primer with an AsiSI site (50-GAGGCGATCGCCATGGGCCAGACTGGGAAG-30)
and a reverse primer with an MluI site (50-GCGACGCGTTCAAGGGATTTCCATTTCTCTTTCGATG-30) to append the cloning sites.
The ORF was cloned into the destination vector pLenti-C-Myc-DDK-IRES-Puro Tagged Cloning Vector (Origene, #PS100069) using
AsiSI (New England Biolabs) and MluI (New England Biolabs). The PCR product was separated by agarose gel electrophoresis and
purified with the QIAquick PCR Purification Kit (250) (QIAGEN, #28106). The PCR product and pLenti-C-Myc-DDK-IRES-Puro
Tagged Cloning Vector were digested with AsiSI and MluI, purified, and ligated using a ligation mix. Transformation was performed
in competent E. coli DH5 a (NIPPON GENE, #310-06236) according to the ECOSTM 1 min/6 min protocol from ECOSTM. Lentivirus
particles were produced using the Lentiviral High Titer Packaging Mix (TaKaRa: 6194) according to the manufacturer’s protocol.
Briefly, the destination vectors and Lentiviral High Titer Packaging Mix were transfected into cells from the Lenti-X 293T Cell Line
(TaKaRa: Z2180N) using Lipofectamine 3000 (Thermo Fisher Scientific). After a 48-hour incubation, the media containing lentivirus
particles were collected and passed through a 0.45-mm filter. To establish EZH2-overexpressing CAFs, CAFs were cultured in com-
plete medium containing virus particles with 4 mg/ml polybrene for 24 hours.
Western blot analysis
Cultured cells were lysed with RIPA buffer containing a protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific). The
lysate was sonicated, the debris were removed by centrifugation, and the supernatant was collected as a whole-cell lysate. Protein
samples were subjected to SDS-PAGE, transferred to PVDF membranes, and blotted with the primary antibodies in Can Get Signal
Solution 1 (Toyobo) at 4C overnight. The signals were detected after an incubation with rabbit or mouse secondary antibodies in
Can Get Signal Solution 2 at room temperature for 1 hour using an ECL Detection System (GE Healthcare, Little Chalfont,Cell Reports 34, 108779, February 23, 2021 e5
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signals was performed with ImageJ software (NIH, USA)
ELISA
Serum levels of CRP in tumor-bearing mice were measured using an ELISA (R&D Systems). The assay procedure was performed
according to the manufacturer’s protocol.
Immunofluorescence and immunohistochemical staining
All tissue slices (4-mm thick) were cut from formalin-fixed, paraffin-embedded tissues andmounted on slide glass. The sections were
prepared for heat-induced antigen retrieval via autoclaving in 1X Antigen Retrieval Solution. All cells were cultured on a 35-mmglass-
bottom dish (Matsunami, Japan). The disheswere fixedwith 4%paraformaldehyde in phosphate buffer and permeabilized with 0.5%
Triton X-100 in PBS. Subsequently, each slide or dish was washed with PBS and stained with the primary antibody overnight at 4C.
For immunofluorescence (IF) staining, the Alexa Fluor 488- or 594-conjugated secondary antibodies were incubatedwith the sections
for 1 hour at room temperature. For immunohistochemistry (IHC), the HRP-conjugated anti-rabbit secondary antibody (Dako, Japan)
was incubated with the sections. The slides were visualized using a BZ-X710microscope (KEYENCE). The antibodies used are listed
in Table S1. Apoptosis was evaluated by performing a TUNEL assay using an In Situ BrdU-Red DNA Fragmentation (TUNEL) Assay
Kit (Abcam, ab66110).
Cell proliferation assay
CAFswere seeded in 96-well plates at a density of 1.03 103 cells/well and incubated at 37Cwith 5%CO2. At 24 hours after seeding,
the CAFswere exposed to pro-inflammatory cytokines (IL1a, IL1b, and TNFa). OCUM-2MD3 cells were seeded into 6-well plates at a
density of 2.03 105 cells/well and incubated at 37Cwith 5%CO2. At 24 hours after seeding, cells were exposed to either S-CAF-CM
or CAF-CM for 48 hours. Cell proliferation was thenmeasuredwith a Luna cell counting plate or using an IncuCyte S3 Livecell Analysis
system (Essen BioScience). For the analysis with the IncuCyte system, CAFs were seeded into 96-well plates and stained with Nuc-
Light Rapid Red (Essen BioScience). The plate was inserted into the IncuCyte instrument for real-time imaging, with four fields
imaged per well every 24 hours over 10 days. Data were analyzed using the IncuCyte software, which quantified the percentage
of red confluence values. All groups were tested in triplicate, and the data are presented as themeans ± standard errors of themeans
(SEM).
Flow cytometry
The cell concentration was adjusted to 1 3 106 cells/ml in PBS containing 2% FBS. The cell suspensions were incubated with an-
tibodies (Table S1) for 30 minutes on ice, washed with PBS containing 2% FBS and centrifuged twice, and the cell pellet was sus-
pended in PBS. Flow cytometry was performed with a FACSVerse instrument (BD Biosciences). The flow cytometry data were
analyzed using FlowJo 3.3 software (Tree Star).
Small interfering RNA (siRNA) transfection
RELA (NFkBp65) and STAT3 expression were downregulated by transfecting cells with predesigned Silencer Select siRNAs directed
against RELA (s11914, Cat# 4427038, Thermo Fisher Scientific) or STAT3 (s744, Cat# 4427038, Thermo Fisher Scientific), and a non-
targeting siRNA (#4390843, Thermo Fisher Scientific) was used as the negative control. CAFswere transfected with annealed siRNAs
for 24-48 hours using Lipofectamine RNAiMAX (#13778-150, Thermo Fisher Scientific).
ROS assay
ROS levels were assayed using the 20,7’-dichlorofluorescin diacetate (DCFDA) cellular ROS assay kit (ab113851, Abcam) according
to the manufacturers’ protocol. Cells were transfected with annealed siRELA (siNFkB p65) for 24 hours, treated with 3CKs for 24
hours, and then cultured with normal medium for 2 days.
Cells were stained with buffer containing 25 mM DCFDA for 30 minutes at 37C. After staining, cells were analyzed using flow
cytometry.
Flow cytometry and cell sorting from ascites
Ascites was obtained from patients who underwent cell-free and concentrated ascites reinfusion therapy (CART) at the Kanamecho
Hospital (Tokyo, Japan). The sample was collected by centrifugation, and red blood cells were lysed using ACK Lysis Buffer. The cells
were adjusted to a concentration of 13 107 cells/ml in PBSwith 2%FBS. Cell suspensions were incubated with antibodies for 30min
at 4C. Cells were stained with a PE-conjugated anti-CD90 (Thy1) antibody (BioLegend, #328110), PE/Cy7-conjugated anti-CD140a
(PDGFRa) antibody (BioLegend, #323507), BV510-conjugated anti-CD326 (EpCAM) antibody (BioLegend, # 324236), and APC-con-
jugated anti-CD45 (HI30) antibody (TOMBO, #20-0459-T025). Dead cells were removed with Zombie Green Fixable Viability Kit
(BioLegend, # 423111). The cells were sorted on the FACSAriaII (BD Biosciences) to obtain CD90+/PDGFa, EpCAM+ and CD45+




Cells sorted by FACS were lysed in 10 mL of cell lysis buffer containing 40 U of RNasin Plus (Promega), Roche Cell Lysis Buffer
(Roche), 10% NP40 (Thermo Fisher), and RNase-free water (TaKaRa). The lysate was centrifuged and mixed using a ThermoMixer
C (Eppendorf) at 2000 rpm for 1 min at 4C. Template RNA was diluted in 10 mL of lysis buffer, denatured for 1.5 min at 70C, and
stored on ice. The reaction buffer for RT was modified using the PrimeScript RT Reagent Kit (TaKaRa). A genomic DNA digestion
solution containing 5 3 RT buffer (TaKaRa), 1 U of DNase I, Amplification Grade (Thermo), and ERCC RNA Spike-In Mix 1 (Thermo)
was added to the sample plate and incubated in a thermal cycler for 5 min at 30C. Amixture containing 53 RT buffer, 203 Enzyme
Mix (TaKaRa), 1 mg/ml T4 gene 32 protein (NBE), 30 mM oligo(dT)18 (Thermo Fisher), and 100 mM 1st NSR primer for human (Sigma)
was added to the template RNA. Themixture was agitated and incubated in a thermal cycler at 25C for 10min, 30C for 10min, 37C
for 30min, 50C for 5min, and 94C for 5min. A second-strand synthesis solution containing 103NBE buffer 2 (NBE), 25mMdNTPs
(TaKaRa), 100 mM 2nd NSR primer for human (Sigma), and Klenow fragment (NBE) was added to the RT product. The mixture was
agitated and incubated in a thermal cycler at 16C for 60 min and at 70C for 10 min. The product was diluted in nuclease-free water
and used for the qPCR analysis.
Mass cytometry
Cells from patients’ ascites were collected as described above. A total of 3.03 106 cells were labeled with Cell-ID Cisplatin (Fluidigm)
to determine whether the cells were alive or dead. Human TruStain FcX (BioLegend) was added to each cell pellet. For staining cell
surface antigens, cells were resuspended in cell staining cocktail (Table S3). Cells were fixed using FixI buffer (Fluidigm) and washed
with Maxpar Perm-S Buffer (Fluidigm). An antibody cocktail (Table S3) was added to stain cytoplasmic antigens. Methanol was
added to each tube for fixation and permeabilization. An antibody cocktail (Table S3) was added to stain nuclear antigens. Cells
were labeled for single-cell discrimination with Cell-ID Intercalator-Ir (Fluidigm). Cells were washed with Maxpar Water (Fluidigm)
and then diluted in water containing 10% EQ Calibration Beads and run on the Helios CyTOF system for sample acquisition.
Mass cytometry data were analyzed using Cytobank software. The viSNE analysis, an application of stochastic neighbor embedding
(SNE), was performed using Cytobank applications employing the Barnes–Hut implementation of t-SNE. Cell populations were iden-
tified utilizing a FlowSOM (Van Gassen et al., 2015) and applying the FlowSOM clustering algorithm on Cytobank. Heatmaps of rela-
tive marker expression were generated using Morpheus from the Broad Institute (https://software.broadinstitute.org/morpheus).
Telomere length quantification
A qPCR assay for quantifying the telomere length was performed using the Absolute Human Telomere Length Quantification qPCR
Assay Kit (ScienCell) according to the manufacturer’s instructions. The average telomere lengths of samples were directly compared
with the reference human genomic DNA sample primer set that recognized and amplified telomere sequences.
SA-b-gal assay
The SA-b-gal assay was performed using a Senescence Detection Kit (BioVision). Cells were fixed with fixative solution and stained
with a staining solution mix (Staining Solution, Staining Supplement, 20 mg/ml X-gal in DMSO) overnight at 37C. Cells were then
washed twice with PBS, and the percentage of stained cells was determined.
QUANTIFICATION AND STATISTICAL ANALYSIS
All experiments were performed in triplicate, and the data shown are representative of consistently observed results. Data are pre-
sented as the mean ± standard deviation (SD). The Mann-Whitney U test was used to compare continuous variables between 2
groups. Data were analyzed using JMP (version 9, SAS Institute, Japan). p value < 0.05 were considered statistically significant.
All p values and n are reported in the figure legends.Cell Reports 34, 108779, February 23, 2021 e7
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Supplementary Figure 1. Characterization of cultured fibroblasts and experimental procedure used 
in this study. Related to Figure 1, 2, 3, 5 and 6. 
(A) Flow cytometry analysis of CD90 expression in NFs and CAFs. (B) RT-qPCR analysis of the 
RHBDF2, IL7R, CADM1, and TM4SF1 mRNAs in NFs and CAFs. Data were normalized to the level of 
the -actin mRNA (**p< 0.01; *p< 0.05, n=6 pairs). (C) Timeline of the experimental procedure for 
sample collection. (D) NFs and CAFs treated with 3CKs had larger and more spindles than the control. 



























Supplementary Figure 2. The involvement of the NFB transcription factor in regulating the 
senescent status of CAFs treated with 3CKs. Related to Figure 1. 
(A) RT-qPCR analysis of the NFkB (p65) mRNA in CAFs transfected with an NFkB (p65) siRNA 
compared to CAFs transfected with the control siRNA (**p < 0.01, n=3). (B) Histograms represent ROS 
levels in CAFs transfected with the NFkB siRNAs and treated with 3CKs relative to CAFs transfected 
with the control siRNA. (C) Immunofluorescence staining for markers of DNA damage (-H2AX and 
pST/Q substrate) together with nuclear staining with DAPI in CAFs transfected with the control siRNA 
or NFkB (p65) siRNA 5 days after the 3CK treatment. Scale bars, 50 m. The graph shows the 
percentage of nuclei with double-positive staining for -H2AX and pST/Q (**p < 0.01, n=3). (D) RT-
qPCR analysis of SASP factors in CAFs transfected with the control siRNA or NFkB (p65) siRNA 3 days 
after the 3CK treatment (**p < 0.01, n=3). 
 
Supplementary Figure 3. The expression of SASP factors induced by 3CKs and by long-term 
passaging. Related to Figure 2. 
(A) RT-qPCR analysis of SASP factors 7 days after the 3CK treatment (**p < 0.01; n.s., not 
significant, n=3). (B) The graphs show the transition of the percentage of SA--gal-positive cells for 
up to twenty-three passages. At least one hundred cells were counted. Representative images of each 
CAF line after early and long passage numbers. Scale bars, 500 m. (C) RT-qPCR analysis of SASP 





Supplementary Figure 4. SASP factors from S-CAFs enhance GC cell growth through JAK/STAT3 
signaling. Related to Figure 3. 
(A) Viability of OCUM-2MD3 cells and NUGC3 cells treated with various concentrations of WP1066 for 
3 days. (B) Viability of WP1066-treated OCUM-2MD3 and NUGC3 cells incubated with or without S-
CAF-CM. We collected S-CAF-CM from S-CAFs induced by 3CKs. (C) RT-qPCR analysis of the 
STAT3 mRNA in OCUM-2MD3 cells transfected with the STAT3 siRNA compared to OCUM-2MD3 
cells transfected with the control siRNA (**p< 0.01, n=3). (D) Growth assays of OCUM-2MD3 cells 
treated with S-CAF-CM, vehicle (DMSO) or WP1066 for 3 days (*p< 0.05; n.s., not significant, n=3). (E) 
RT-qPCR analysis of the STAT3 mRNA in NUGC3 cells transfected with the STAT3 siRNA compared 
to NUGC3 cells transfected with the control siRNA (**p< 0.01, n=3). (F) Growth assays of NUGC3 cells 








Supplementary Figure 5. Three labelled populations from ascites of patients with GC and the p16 
expression level in CD90(+) fibroblasts. Related to Figure 4. 
(A) Flow charts showing the gating strategy for sorting each labelled population (CD90/PDGFR, 
EpCAM, and CD45) from ascites from patients with GC used for the analysis of SASP expression. (B) 



































Supplementary Figure 6. IL-6 activates JAK/STAT3 signaling and promotes peritoneal tumor 
formation by inhibiting apoptosis without harm. Related to Figure 5. 
(A) Body weight changes after daily intraperitoneal injections of CAF-CM or S-CAF-CM compared to 
animals injected with the normal medium. No significant difference in mouse body weight was observed 
among the three groups during treatment. (B) Representative images of OCUM-2MD3-bearing mice 
treated with vehicle (NM) or IL-6 (200 ng/mouse) a total of 12 times for 30 days. The graph shows the 
quantification of the tumor masses of each group (day 30) (*p< 0.05, NM, n=6; IL-6, n=8). (C) Body 
weight changes after treatment with vehicle or IL-6. No significant difference in mouse body weight was 
observed during treatment. (D) Immunofluorescence staining for the TUNEL analysis of the implanted 
OCUM-2MD3 cells in each group. The graph shows the quantification of the positive staining rate (*p< 
0.05, n=3). (E) WB analysis of p-STAT3 and Bcl-2 levels in the implanted OCUM-2MD3 cells in each 
group. The graph shows the normalization of p-STAT3 levels to total STAT3 levels and the 
normalization of Bcl-2 levels to total -actin levels (*p< 0.05, n=3). (F) Body weight changes after 
treatment with S-CAF-CM or Ezh2 O/E-CAFs-CM. No significant difference in mouse body weight was 























Supplementary Figure 7. The JAK/STAT3 inhibitor effectively blocks the peritoneal tumor 
formation enhanced by S-CAFs, but have no effect on that without S-CAFs. Related to Figure 6. 
(A) Representative images of OCUM-2MD3-bearing mice treated with vehicle (DMSO) or 20 mg/kg 
WP1066 a total of 8 times for 3 weeks. The graph shows the quantification of the tumor masses in each 
group (n.s., not significant, NM; n=6, WP1066; n=8). (B) Body weight changes after treatment with 
vehicle (DMSO) or WP1066. No significant difference in mouse body weight was observed during 
treatment. (C) WB analysis of p-STAT3 and Bcl-2 levels in implanted OCUM-2MD3 cells from each 
group. The graph shows the normalization of p-STAT3 to total STAT3 levels and the normalization of 
Bcl-2 to total -actin levels (n.s., not significant, n=3). (D) The graph shows the quantification of the 
tumor masses in each group (**p< 0.01, S-CAF; n=5, S-CAF+WP; n=8). (E) Body weight changes after 
daily injections of S-CAF-CM and treatment with vehicle (DMSO) or WP1066. No significant difference 




Table S1. Antibody sources and concentrations related to STAR 
Methods. Related to Figure 1 to 6.  

























5174 1:1000       
p16 INK4A Abcam ab108349 1:5000       
p15 INK4B Santa Cruz sc271791 1:1000       
 Lamin B1 Abcam ab16048 1:1000       
 -Tubulin Abcam ab7291 1:5000       
 Histone3 Abcam ab1791 1:10000       
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BioLegend 324236       1:100 
 CD45 TOMBO 
20-0459- 
T025 











Santa Cruz sc2005   1:5000     
Alexa Fluor 





A11008     1:200   
Alexa Fluor 





A11005     1:200   
 
 
Table S2. Primer/probe information. Related to Figure 2 and 4. 
Official 
Symbol 








ACTB -actin attggcaatgagcggtt cgtggatgccacaggact #11 
IL6   caggagcccagctatgaact gaaggcagcaggcaacac #7 
CCL20   gctgctttgatgtcagtgct gcagtcaaagttgcttgctg #39 
CSF2   cagccactacaagcagcact ccggtctcactcctggac #3 
IL8   agacagcagagcacacaagc atggttccttccggtggt #72 
VEGFA   cctccgaaaccatgaacttt atgattctgccctcctcctt #22 
EGF   gctggggatggaaaactatg cttcggtgttgatgcacttg #16 
RHBDF2 iRhom2 gggcaaactcagactcgaag tcccgccattcttgtcag #51 
IL7R   aaagttttaatgcacgatgtagctt tgtgctggataaattcacatgc #72 
CADM1   ggtggttcaaagggaacaca cacagtgtacatgtctgaccactc #10 
TM4SF1   tttctggcatcgtaggaggt ccagcccaatgaagacaaat #51 
RELA NFB p65 cgggatggcttctatgagg ctccaggtcccgcttctt #47 
STAT3   gagcagagatgtgggaatgg cggtctcaaaggtgatcagg #17 
 
 
Table S3. Antibodies used for mass cytometry. Related to Figure 4. 
Target Metal tag clone   Manufacturer Catalog  
number 
  
CD90 159Tb 5E10   Fluidigm 3159007B For cell surface 
molecules PDGFR 
(CD140A) 
160Gd D13C6   Fluidigm 3160007A 
CD326 
(EpCAM) 
141Pr 9C4   Fluidigm 3141006B 
CD45 89Y HI30   Fluidigm 3089003B 
CD4 176Yb RPA-T4   Fluidigm 3176010B 
CD8a 146Nd RPA-T8   Fluidigm 3146001B 
CD11b 
(Mac-1) 
167Er ICRF44   Fluidigm 3167011B 






antibody [EPR1473] – 
BSA- and azide-free 
(ab186932) 
Abcam ab186932 For nuclear 
molecules 
 
 
 
 
